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Anemia is frequent in chronic heart failure (HF). To calculate what change in peak oxygen uptake ( _VO2)
should be expected in the event of changes in hemoglobin concentration, we studied the correlation
between peak _VO2 and hemoglobin concentration in a large HF population. We carried out retrospective
analysis of all cardiopulmonary exercise tests (CPET) performed in our HF Clinic between June 2001 and
March 2009 in HF patients who had a resting hemoglobin concentration measurement taken within 7 days
of the CPET. We collected 967 CPETs, 704 tests were considered maximal and analyzed. We identiﬁed 181
patients (26%) as anemic. Peak _VO2 was lower (P < 0.001) in anemic patients (971 ± 23 ml/min) compared
with nonanemic (1243 ± 18 ml/min). The slope of the _VO2 vs. hemoglobin ratio was 109 ml/min/g/dl at peak
exercise. This correlation remained signiﬁcant also when several confounding variables were analyzed by
multivariate analysis. As an average, each gram of hemoglobin accounts, at peak exercise, for 109 ml/min
change in _VO2 which is equivalent to 0.97 ml/min/kg. Therefore, in HF patients anemia treatment should
increase _VO2 by 109 ml/min for each g/dl of hemoglobin increase. Am. J. Hematol. 85:414–417,
2010. VC 2010 Wiley-Liss, Inc.
Introduction
Anemia and reduction of exercise capacity are both fre-
quently reported in chronic heart failure (HF) and are both
associated to worsening of HF prognosis [1–4]. The two
are linked to each other indirectly, having heart failure as a
common underlying origin, and directly. Indeed, the gold
standard variable of exercise capacity evaluation is peak
exercise oxygen uptake ( _VO2), which is a cardiac output x
arterio-venous O2 difference. The latter depends on hemo-
globin, which reduction negatively affects the arterial oxy-
gen concentration. Furthermore several reports showed
that, in chronic HF patients, anemia is associated with low
exercise capacity [5,6]. In principle, it is possible to calcu-
late the amount of peak _VO2 loss due to anemia if hemo-
globin arterial oxygen saturation is normal, and if peak
exercise cardiac output and peak exercise oxygen extrac-
tion are known. In 2 previous studies of our group in HF
patients, we measured at peak exercise a mean extraction
rate 70% [7,8]. Therefore, because 1 g of hemoglobin
binds 1.34 ml of oxygen and, at peak exercise extraction
rate is 70%, each gram of hemoglobin provides to the
muscles 1 ml of oxygen. The latter multiplied by the car-
diac output is the amount of _VO2 reduction resulting from a
1 g drop in hemoglobin [9]. For example, if peak exercise
cardiac output is 10 l/min the loss of 1 g of hemoglobin is
equivalent to a reduction of 100 ml/min _VO2. Unfortu-
nately, neither cardiac output nor oxygen extraction at peak
exercise are usually measured, so that we cannot calculate
the reduction of _VO2 directly due to anemia. It would be de-
sirable, however, to understand, at least in a semi-quantitative
fashion, the role of anemia on peak _VO2 in HF patients. This
study was undertaken to evaluate the correlation between
peak exercise _VO2 and hemoglobin concentration in a large
HF population.
Methods
We carried out retrospective analysis of all cardiopulmonary exercise
tests (CPET) performed in our HF Clinic between June 2001 and
March 2009 in HF patients in stable clinical conditions, NYHA Class I
to III, with left ventricle ejection fraction 50% who had performed a
resting hemoglobin concentration measurement in our general labora-
tory within 7 days of the exercise test. We excluded subjects with his-
tory and/or clinical documentation of pulmonary embolism or primary
valvular heart disease, pericardial disease, severe obstructive lung dis-
ease, primitive pulmonary hypertension or occupational lung disease,
asthma, severe renal failure (serum creatinine >5 mg/dl), signiﬁcant
peripheral vascular disease, advanced atrio-ventricular block, exercise-
induced angina and/or relevant ST changes. We also excluded patients
whose exercise was interrupted as the result of a medical decision
before maximal effort was reached, due to severe hypertension or
severe arrhythmia.
CPETs were performed on a cycle-ergometer using a progressively
increasing work load generated by a ramp protocol personalized for
each patient, with the aim of reaching maximum exercise in about 10
min. Subjects were asked to pedal at 60 revolutions per minute. The
used load for each individual of the personalized ramp protocol was
decided by the physician in charge according to previous test results,
if available, or to exercise performance as reported by patients. Tests
too short (<5 min) or too long (>14 min) were repeated with a more
appropriate ramp protocol [10]. Ventilation ( _VE), _VO2, and carbon
dioxide production ( _VCO2) were measured breath by breath (V-max
2900 metabolic cart SensorMedics, Yorba Linda CA for tests per-
formed between June 2001 and August 2004 and V-max metabolic
cart SensorMedics, Yorba Linda CA for tests performed between Sep-
tember 2004 and March 2009). Twelve-leads ECG and heart rate were
monitored continuously. Anaerobic threshold was measured by the V-slope
method and conﬁrmed by O2 and CO2 ventilatory equivalents and end-
tidal O2 and CO2 pressure speciﬁc changes [11]. _VE/ _VCO2 slope was
measured from the beginning of loaded pedaling to the end of the iso-
capnic buffering period. The latter was identiﬁed by an increase of the
ventilatory equivalent for CO2 ( _VE/ _VCO2) and conﬁrmed by reduction of
end-tidal CO2 pressure. The _VO2/work ratio was measured throughout
the entire exercise.
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Echocardiography was performed in our laboratory on each patient
within 6 months of the CPET test. Left ventricular diastolic volume and
ejection fraction were measured in the left lateral decubitus position.
Left ventricular volume was derived from the conventional apical 2- and
4-chamber images and the left ventricle ejection fraction was calculated
using biplane Simpson’s technique [12].
Anemia was deﬁned by WHO criteria as hemoglobin concentration
<12 g/dl in women and <13 g/dl in men [13]. The presence of coro-
nary artery disease associated to HF was assessed by standard cor-
onary angiography according to Felker et al. [14]. We considered
only coronary angiography performed within one year of the CPET. In
case of multiple exercise tests we selected the CPET used in the present
analysis in a random manner. The study and the access of private health
information were approved by the local intern review board.
Statistical analysis. Data are reported as mean ± SE. Differences
between groups were analyzed by unpaired t-tests with a P < 0.05
considered as statistically signiﬁcant. Categorical variables such as
NYHA classiﬁcation, gender differences or treatment were analyzed
by chi-square test. Correlation between variables was assessed by
linear regression analysis. We evaluated vs. peak _VO2 several varia-
bles including: age, gender, NYHA class, left ventricle ejection fraction,
_VE/ _VCO2 slope, peak heart rate and work load. Multivariate analysis
was performed adding in the model all variables which were corre-
lated to peak _VO2 at monovariate analysis. A similar analysis was
also performed using _VO2 at the anaerobic threshold as the depend-
ent variable.
All data were analyzed by SPSS 17.0 software collected in an Excel
data base.
Results
We collected a total of 967 CPETs of HF patients who
matched the clinical study criteria, who had both a blood
test for hemoglobin concentration determination at rest
taken at our central laboratory within one week and an
echocardiographic evaluation taken within 6 months. 263
CPETs were discarded because effort was judged submax-
imal according to peak exercise gas exchange ratio (RQ <
1.05). Consequently, 704 patients were considered in this
report. Population characteristics, treatment and heart fail-
ure severity are reported in Table I. Anemic patients were
older, had clinically more severe HF and were more fre-
quently treated with diuretics.
Haemoglobin was 13.7 ± 0.1 g/dl ranging between 7.5
and 17.1 g/dl. One hundred eighty-one patients were ane-
mic (26%), representing 33 (25%) of 133 women and 148
(26%) of 571 males. Nonanemic patients were 523 (74%),
representing 100 (75%) of 133 women, and 423 (74%) of
571 males. Anaerobic threshold was not identiﬁed in 12%
(n 5 87) of the 704 patients. CPET results are reported in
Table II for the entire study population and for the anemic
and nonanemic patients, respectively. Anemic patients had
a lower exercise capacity, with the work load achieved, the
_VO2 both at peak exercise and at anaerobic threshold
being lower. Furthermore, anemic HF patients had a
greater _VE/ _VCO2 slope. It should be noted that cardiac
function and left ventricular volume at echocardiography
were similar for anemic and nonanemic patients (Table I).
Peak _VO2 was lower in anemic male patients compared
with nonanemic but not in women who showed only a trend
toward the same difference (P 5 0.0506) (Fig. 1).
TABLE II. Cardiopulmonary Exercise Test Results
Total population Anemic Not-anemic P
Peak _VO2 (ml/min) 1173 ± 15 971 ± 23 1243 ± 18 <0.001
Peak _VO2 (ml/Kg/min) 15.3 ± 0.2 13.2 ± 0.3 16.0 ± 0.2 <0.001
Peak _VO2 (% of predicted value) 60 ± 01 51 ± 1 63 ± 1 <0.001
_VE/ _VCO2 slope 31 ± 0 34 ± 1 31 ± 0 <0.001
_VO2 /Work (ml/min Watt) 9.6 ± 0.3 9.4 ± 0.4 9.7 ± 0.3 N.S.
_VO2 AT (ml/min) 807 ± 11 680 ± 18 849 ± 13 <0.001
HR at rest (b/min) 74 ± 1 73 ± 1 74 ± 1 N.S.
HR max (b/min) 120 ± 1 111 ± 2 123 ± 1 <0.001
Delta HR (b) 47 ± 1 38 ± 2 49 ± 1 <0.001
Work load (Watt) 89 ± 1 71 ± 2 95 ± 2 <0.001
Exercise time (min) 8.8 ± 0.1 7.9 ± 0.1 9.1 ± 0.2 <0.001
_VO2 5 oxygen uptake; _VE / _VCO2 5 ventilation/carbon dioxide slope; AT 5
anaerobic threshold; HR 5 heart rate.
TABLE I. HF Patients Characteristics
Total population
n 5 704
Anemic
n 5 181
Not-anemic
n 5 523 P
Age (year) 62.8 ± 0.4 65.3 ± 0.8 61.9 ± 0.5 <0.001
Gender
m 571 (81%) 148 (26%) 423 (74%) N.S.
f 133 (19%) 33 (25%) 100 (75%) N.S.
NYHA
I 101 10 (5%) 91 (17%) <0.001
II 297 59 (33%) 238 (46%)
III 306 112 (62%) 194 (37%)
LVEF (%) 35.4 ± 0.3 35.3 ± 0.6 35.5 ± 0.4 N.S.
LVDV (ml) 189 ± 3 190 ± 5 189 ± 3 N.S.
Hemoglobin (g/dl) 13.6 ± 0.06 11.7 ± 0.07 14.3 ± 0.05 <0.001
Weight (Kg) 76.7 ± 0.5 73.8 ± 1 77.7 ± 0.6 0.001
Therapy
B-Blockers 592 (84%) 151 (83%) 441 (84%) N.S.
Diuretics 513 (73%) 157 (87%) 356 (68%) <0.001
Ace-inhibitor 525 (75%) 133 (73%) 392 (75%) N.S.
ARBs 135 (20%) 40 (22%) 95 (18%) N.S.
Spironolactone 341 (50%) 94 (52%) 247 (47%) N.S.
LVEF 5 left ventricular ejection fraction; LVDV 5 left ventricular diastolic volume.
Figure 1. Peak oxygen uptake in anemic (white bar) and not anemic (black bar)
HF patients. Entire HF population (upper panel), HF males (middle panel), and HF
females (lower panel). * 5 P < 0. 05.
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Coronary angiography was available for 692 of the 704
patients. 332 (47%) patients (30 female and 302 male)
were classiﬁed as having HF associated to coronary artery
disease and 360 (53%) (102 female and 258 male) as not
associated to coronary artery disease, i.e., with angiograﬁ-
cally normal epicardial coronary arteries. The presence of
coronary artery disease did not signiﬁcantly inﬂuenced the
correlation between _VO2 and hemoglobin both at peak
exercise and at anaerobic threshold (Table III). Table IV
shows the correlations between several variables and peak
_VO2. At multivariate analysis only gender (P < 0.000), he-
moglobin (P < 0.01), _VE/ _VCO2 slope (P < 0.000), the work
load achieved (P < 0.000) and NYHA class (P < 0.000)
remained signiﬁcantly correlated to peak _VO2.
The correlation between peak exercise _VO2 and hemo-
globin at rest is reported in Fig. 2. Assessing _VO2 as ml/
min/kg the slope of the _VO2 vs. hemoglobin relationship
was 0.97 (ml/kg/min/g/dl). _VO2 at anaerobic threshold was
signiﬁcantly correlated to the following variables: age (P <
0.000), gender (P < 0.000), NYHA class (P < 0.000),
LVEF (P < 0.000), hemoglobin (P < 0.000), _VE/ _VCO2
slope (P < 0.000), peak heart rate (P < 0.000), and work
load (P < 0.000). At multivariate analysis only age (P <
0.05), _VE/ _VCO2 slope (P < 0.000), and work load (P <
0.000) remained independently correlated to _VO2. The _VO2
vs. Hb relationship at the anaerobic threshold is reported in
Fig. 3.
Discussion
This study shows, in accordance with several previous
reports, that anemia is frequent in chronic HF patients and
associated with a lower exercise capacity [1–6]. Indeed, the
prevalence of anemia we observed (26%) is in agreement
with what has been reported previously (between 10 and
55%) [4]. In HF the presence of anemia is associated with
poor prognosis, with higher mortality risk both in hospitalized
and ambulatory patients, higher hospitalization rate and, over-
all, with a more severe clinical condition for patients [4,15–17].
In our study, on average, peak _VO2 and _VE/ _VCO2 slope, both
of which are independent strong prognostic indicators of HF
[18], were 22% lower and 10% higher, respectively, in HF
patients with anemia compared with those without anemia.
It is commonly thought that anemia should be corrected
to improve HF patients’ quality of life and possibly progno-
sis, however, there is still a lack of a scientiﬁc evidence;
consequently, anemia correction is not considered as man-
datory in HF treatment guidelines [19,20]. Several studies
have focused on the effect of anemia correction, usually by
iron and erythropoietin or darbopoietin, on exercise per-
formance, measured either by peak _VO2, exercise toler-
ance or by distance walked at the 6 min walking test, in
both HF and non-HF patients [21–29]. However, only four
[21–23] reports all based on small studies, showed the
effect of anemia correction on peak exercise _VO2 in HF
patients, with discordant ﬁndings. Indeed, three reports
showed that anemia treatment increased exercise perform-
ance [21,22,24] while one did not [23].
Several factors inﬂuence exercise performance in HF,
including, following the Fick principle, cardiac output and
the arterio-venous oxygen difference. We limited our analysis
only to hemoglobin. To extrapolate the role of hemoglobin,
we studied the correlation between resting hemoglobin and
_VO2 at peak and anaerobic threshold. We observed a cor-
relation between _VO2 (ml/min) at peak and hemoglobin with
a R2 5 0.18, which means that hemoglobin accounts for
18% of the variance in peak _VO2. This also means that 82%
of peak _VO2 variance is not related to hemoglobin. The slope
of this ratio (Fig. 2) tells us that, on average, at peak exercise
each gram of hemoglobin accounts for a 109 ml/min change
in _VO2 which is equivalent to 0.97 ml/min/kg.
We analyzed the correlation between _VO2 at peak exer-
cise and resting hemoglobin. Unfortunately peak exercise
hemoglobin data is not available. However, exercise-
induced hemoconcentration, which is well known and is
TABLE III. Linear Regressions Between Peak _VO2 and _VO2 at the Anaerobic Threshold vs. Hemoglobin at Rest
Total population HF1CAD HF no-CAD
Peak _VO2 5 109 Hb 2 3189 R
2 5 0.180 Peak _VO2 5 94 Hb 2 161 R
2 5 0.168 Peak _VO2 5 116 Hb 2 363 R
2 5 0.182
_VO2 AT 5 74 Hb 2 200 R
2 5 0.169 _VO2 AT 5 61 Hb 2 60 R
2 5 0.146 _VO2 AT 5 82 Hb 2 284 R
2 5 0.191
_VO2 (ml/min) 5 oxygen uptake; AT 5 anaerobic threshold; HF 5 heart failure; CAD 5 coronary artery disease; Hb (g/dl) 5 hemoglobin.
Figure 2. Linear regression between peak _VO2 (oxygen uptake) and hemoglobin
concentration in HF patients (n 5 704).
TABLE IV. Monovariate Correlations Between Peak _VO2 and Several
Variables
R2 P
Age 0.197 <0.000
Gender 0.110 <0.000
LVEF(%) 0.08 <0.000
Hb (g/dl) 0.108 <0.000
_VE/ _VCO2 slope 0.2 <0.000
HR peak (b/m) 0.192 <0.000
Work load (Watts) 0.872 <0.000
NYHA class 0.589 <0.000
_VO2 5 oxygen uptake; _VE/ _VCO25 ventilation/carbon dioxide slope; HR 5 heart
rate; Hb 5 hemoglobin.
Figure 3. Linear regression between _VO2T (oxygen uptake at anaerobic thresh-
old) and hemoglobin concentration in HF patients (n 5 617).
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due to both spleen contraction and ﬂuid shift away from the
intravascular space due to an increase in intracellular lactic
acid (30,31), probably did not signiﬁcantly inﬂuence our
ﬁndings. Indeed, exercise-induced hemoconcentration is re-
sponsible for approximately 20% of arterio-venous oxygen
difference increase in HF subjects, being on average
around 1.0 g/dl in normal subjects and 0.6 g/dl in HF
patients (30). Had the exercise-induced hemoglobin
increase been even in patients with different levels of HF
severity, this would have only shifted the _VO2/Hb ratio
upward, with no effect on the slope of the ratio and, conse-
quently, with no effect on the predicted _VO2 change as a
result of hemoglobin changes. Unfortunately this is not the
case, because exercise-induced hemoglobin increase is
greater in less compromised patients, so the lack of hemo-
globin measurements at peak exercise weakens our results.
However, when comparing severe and non-severe HF
patients the difference in exercised-induced hemoglobin
increase is trivial (30) and certainly not able to have a sig-
niﬁcant effect on our results.
Data at anaerobic threshold were analyzed because
exercise-induced hemoconcentration takes place above
the anaerobic threshold. The relationship between _VO2
at anaerobic threshold and hemoglobin at rest is more
shallow than the one observed at peak exercise being the
slope 74 and 109 ml/min/g/dl, respectively. Furthermore at
multivariate analysis the relationship between resting he-
moglobin and _VO2 AT loses the statistical signiﬁcance.
Indeed, at the anaerobic threshold, hemoglobin has a
lower role in determining _VO2 compared to _VO2 at peak
exercise. This ﬁnding is not surprising considering that, at
the anaerobic threshold, a reduction in oxygen delivery
due to anemia can be still partially counteracted by an
increase in cardiac output.
This study has some structural limitations, which should
be acknowledged. Indeed, the cross sectional nature of this
study does not permit to deﬁne, but only to suggest, a
causal relationship between hemoglobin levels and exercise
capacity. Finally, we had described a relationship for a pop-
ulation but this may not be an appropriate prediction in a
single individual.
In conclusion our data show that, analyzing a relevant
number of HF patients, a correlation between peak _VO2
and hemoglobin exists with a slope equal to 109 ml/min/g/
dl. Thus, albeit totally unproven, it is possible to suggest
that _VO2 should increase by approximately 109 ml/min for
each g/dl of hemoglobin increase. Studies analyzing the
acute effects of hemoglobin changes on exercise perform-
ance in anemic HF patients are needed.
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